Search

Search Constraints

You searched for: Author/Creator Chéret, Antoine

Search Results

1. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment. (11th September 2021)

2. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. (21st April 2015)

3. Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1–Infected Patients with Central Nervous System Impairment. (3rd June 2019)

4. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies. (26th February 2015)

5. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Issue 4 (April 2015)

6. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Issue 4 (April 2015)

7. Motivational interviewing training for medical students: A pilot pre-post feasibility study. Issue 11 (November 2018)

8. NKG2C+ memory‐like NK cells contribute to the control of HIV viremia during primary infection: Optiprim‐ANRS 147. Issue 7 (7th July 2017)

9. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. (28th June 2022)

10. Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors. (28th November 2018)